Literature DB >> 15908170

A novel anti-tumor agent, polyoxomolybdate induces apoptotic cell death in AsPC-1 human pancreatic cancer cells.

A Ogata1, S Mitsui, H Yanagie, H Kasano, T Hisa, T Yamase, M Eriguchi.   

Abstract

Anti-tumoral polyoxomolybdates have been investigated in the course of study of the medical application of polyoxometalates as discrete cluster anions of metal oxides. [NH(3)Pr(i)](6)[Mo(7)O(24)].3H(2)O (PM-8) has been recognized as one of significantly anti-tumoral polyoxomolybdates. PM-8 inhibited the cell growth of human pancreatic cells (AsPC-1) depending on the dose. DNA ladder formation and DNA fragmentation were observed by Hoechst and TUNEL staining and flowcytometry analysis. The ratio of apoptotic cells were 29%, 35%, and 57% with treatment of PM-8 after 24, 48, and 72 h, respectively, which suggested that the anti-tumor activity of PM-8 results from the activation of the apoptotic pathway. Polyoxomolybdates provide promising, novel anti-tumor agent, especially for the treatment of cancers that are difficult to treat.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908170     DOI: 10.1016/j.biopha.2004.11.008

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results.

Authors:  Amandine Boulmier; Xinxin Feng; Olivier Oms; Pierre Mialane; Eric Rivière; Christopher J Shin; Jiaqi Yao; Tadahiko Kubo; Taisuke Furuta; Eric Oldfield; Anne Dolbecq
Journal:  Inorg Chem       Date:  2017-06-20       Impact factor: 5.165

2.  Selected polyoxopalladates as promising and selective antitumor drug candidates.

Authors:  Andjelka M Isakovic; Mirjana B Čolović; Tian Ma; Xiang Ma; Marija Jeremic; Marko Gerić; Goran Gajski; Sonja Misirlic-Dencic; Ulrich Kortz; Danijela Krstić
Journal:  J Biol Inorg Chem       Date:  2021-09-21       Impact factor: 3.358

3.  Cation-mediated optical resolution and anticancer activity of chiral polyoxometalates built from entirely achiral building blocks.

Authors:  Zhi-Ming Zhang; Xiaopin Duan; Shuang Yao; Zhishu Wang; Zekai Lin; Yang-Guang Li; La-Sheng Long; En-Bo Wang; Wenbin Lin
Journal:  Chem Sci       Date:  2016-03-09       Impact factor: 9.825

4.  The Aquaporin-3-Inhibiting Potential of Polyoxotungstates.

Authors:  Catarina Pimpão; Inês V da Silva; Andreia F Mósca; Jacinta O Pinho; Maria Manuela Gaspar; Nadiia I Gumerova; Annette Rompel; Manuel Aureliano; Graça Soveral
Journal:  Int J Mol Sci       Date:  2020-04-02       Impact factor: 5.923

5.  Highly Selective and Tunable Protein Hydrolysis by a Polyoxometalate Complex in Surfactant Solutions: A Step toward the Development of Artificial Metalloproteases for Membrane Proteins.

Authors:  Annelies Sap; Laurens Vandebroek; Vincent Goovaerts; Erik Martens; Paul Proost; Tatjana N Parac-Vogt
Journal:  ACS Omega       Date:  2017-05-11

6.  Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus.

Authors:  Hong Zhang; Yanfei Qi; Yanhua Ding; Juan Wang; Qingmei Li; Jingzhou Zhang; Yanfang Jiang; Xiumei Chi; Juan Li; Junqi Niu
Journal:  Bioorg Med Chem Lett       Date:  2012-01-02       Impact factor: 2.823

Review 7.  Polyoxometalates active against tumors, viruses, and bacteria.

Authors:  Toshihiro Yamase
Journal:  Prog Mol Subcell Biol       Date:  2013

8.  Poly (N-vinylpyrrolidone) modification mitigates plasma protein corona formation on phosphomolybdate-based nanoparticles.

Authors:  Youyi Yu; Behafarid Ghalandari; Guangxia Shen; Liping Wang; Xiao Liu; Aiting Wang; Sijie Li; Haiyang Xie; Xianting Ding
Journal:  J Nanobiotechnology       Date:  2021-12-23       Impact factor: 10.435

9.  Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models.

Authors:  A Ogata; H Yanagie; E Ishikawa; Y Morishita; S Mitsui; A Yamashita; K Hasumi; S Takamoto; T Yamase; M Eriguchi
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.